Search
Atea Pharmaceuticals Inc
AVIRAdd to Watchlist
5.310USD
+0.130+2.51%
Close 09-11 16:00（ET）
426.69MMarket Cap
LossP/E TTM
Atea Pharmaceuticals Inc (AVIR) Stock Price Target & Forecast
Analyst Rating
Based on 3 analysts giving stock ratings to Atea Pharmaceuticals Inc in the past month.
Buy
1 Strong Buy
1 Buy
1 Hold
0 Sell
0 Strong Sell
Target Price
8.500USD+61.29%
AVIR Analyst Recommendation Trends
In the current month, AVIR has received 1 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. AVIR average Analyst price target in the last month is 8.500.
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
2026-03
2026-02
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
3
3
3
3
3
3
3
3
AVIR Analyst Rating for Peer Comparison
Updated: Sep 11, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
Beigene Ltd
ONC
8
19
0
0
0
27
argenx SE
ARGX
10
13
3
0
0
26
Ionis Pharmaceuticals Inc
IONS
6
14
5
0
0
25
IQVIA Holdings Inc
IQV
7
12
6
0
0
25
CRISPR Therapeutics AG
CRSP
4
9
11
0
0
24
Insmed Inc
INSM
7
17
0
0
0
24
Kymera Therapeutics Inc
KYMR
8
13
2
0
0
23
Cytokinetics Inc
CYTK
4
16
2
0
0
22
Revolution Medicines Inc
RVMD
8
12
1
0
0
21
Ascendis Pharma A/S
ASND
10
10
0
0
0
20
Financial Forecasting
Based on analysts' estimates, AVIR EPS is projected to reach -0.420 in FY2026Q3, following reported EPS of -0.411 in FY2026Q2. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2025Q4
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
Forecast
-0.53
-0.59
-0.56
-0.42
-0.42
Actual
-0.57
-0.57
-0.41
--
--
Surprise
-8.38%
+2.75%
+26.54%
--
--
FAQs
What is Atea Pharmaceuticals Inc's price target?
Analysts forecast that Atea Pharmaceuticals Inc's price target is USD 8.50, with the highest forecast at USD 10.00 and the lowest forecast at USD 7.00.
How have Atea Pharmaceuticals IncAVIR's recent earnings per share performed?
The market expectation was USD -0.41, while Atea Pharmaceuticals IncAVIR's earnings per share (EPS) for the previous quarter was USD -0.57. EPS for the next quarter is expected at USD -0.42.
What is the analyst rating for Atea Pharmaceuticals Inc?
Based on the ratings of Atea Pharmaceuticals Inc's stock from 3 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.